DAX-0,60 % EUR/USD-0,12 % Gold-0,06 % Öl (Brent)0,00 %

New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions

Nachrichtenquelle: GlobeNewswire
30.04.2019, 22:30  |  546   |   |   

Novartis International AG / New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

  • Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple sclerosis (MS) and migraine
     
  • Interim data from multiple ongoing clinical studies of Zolgensma*(onasemnogene abeparvovec-xioi; AVXS-101) show positive results in the treatment of SMA[1]-[12]
     
  • EXPAND analyses show people with secondary progressive MS (SPMS) taking Mayzent (siponimod) - the only therapy proven to delay disability progression in a study of typical SPMS patients - experienced significant benefits on cognitive function[13]
     
  • With the greatest real world exposure and longest clinical trial experience of any anti-CGRP therapy, Aimovig (erenumab) continues to show positive long-term safety and efficacy across the spectrum of migraine with new clinical trial data[14]-[22]
  • Basel, April 30, 2019 - Novartis announced today it will present 53 abstracts from across its unique neurological portfolio and pipeline at the upcoming 71st American Academy of Neurology (AAN) meeting May 4 - 10 in Philadelphia, Pennsylvania, USA. The breadth and depth of the data highlights the company's commitment to decoding the science behind neurological diseases such as spinal muscular atrophy (SMA), multiple sclerosis (MS) and migraine.  

    "Our presence at AAN this year is a testament to how we are reimagining medicine across a broad spectrum of neurological diseases, for many patients of all ages," said Danny Bar-Zohar, Global Head, Neuroscience Development for Novartis Pharmaceuticals. "Nothing is more rewarding than combining cutting-edge science, advanced algorithms and technology with a relentless ambition to bring life-changing solutions to people who need them."

    Novartis highlights at AAN include:

    Spinal muscular atrophy[1]-[12]:

    • Four new scientific abstracts spanning the clinical development program for the investigational gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) show positive results in the treatment of SMA.
    • Interim data presented for the first time from the Phase I STRONG trial demonstrated encouraging results via the intrathecal delivery in patients with SMA Type 2. 
    • New interim data from the Phase III STR1VE study demonstrated survival and motor function improvements that continue to parallel the Phase I START study.
    • Preliminary data from the Phase III SPR1NT trial demonstrated significant motor function improvements in pre-symptomatic SMA patients.
    • Data from the ongoing long-term follow-up study for the Phase I START trial show no waning of motor milestone achievements in patients with SMA Type 1.
    • Three health economics studies demonstrated improved survival and milestone achievement with Zolgensma.
    • New data supporting the potential use of serum neurofilament light chain as biomarker for SMA Type 1 disease activity and therapy response under branaplam (LMI070), an oral, once-weekly RNA splicing modulator.

    Zolgensma was granted Priority Review for the treatment of SMA Type 1 by the FDA and regulatory action is anticipated in May 2019.

    Schreibe Deinen Kommentar

    Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

     

    Disclaimer

    Meistgelesene Nachrichten des Autors

    Titel
    Titel
    Titel
    Aus der Community
    LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
    Chart: arniarni
    LUS Wikifolio-Index BITCOIN performance Index Zertifikat Open-End (LASW)
    Chart: arniarni
    LUS Wikifolio-Index BITCOIN, ETHEREUM & GOLD Index Zertifikat Open-End (LASW)
    Chart: arniarni